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The regulation of iron absorption is of considerable interest in mammals since excretion is minimal. Recent advances in iron metabolism have
expounded the molecular mechanisms by which iron absorption is attuned to the physiological demands of the body. The pinnacle was the
discovery and identification of hepcidin, a hepatic antimicrobial peptide that regulates absorption to maintain iron homeostasis. While the
intricacies of its expression and regulation by HFE, transferrin receptor 2 and hemojuvelin are still speculative, hepcidin responsiveness has
correlated negatively with iron absorption in different models and disorders of iron metabolism. Consequently, hepcidin expression is repressed to
enhance iron absorption during stimulated erythropoiesis even in situations of elevated iron stores. Animal models have been crucial to the
advances in understanding iron metabolism and the present review focuses on phenylhydrazine treated and hypotransferrinaemic rodents. These,
respectively, experimental and genetic models of enhanced erythropoiesis highlight the shifting focus of iron absorption regulation from the
marrow to the liver.
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Iron deficiency is the most prevalent cause of anaemia,
affecting 15% of the world's population [1]. Mammalian
iron homeostasis is essentially a balance of the iron
metabolism of haemoproteins, erythropoeisis, reticuloendo-
thelial and the storage compartments. Haemoglobin, myo-
globin and other haemoproteins constitute 85% of the total
body Fe content, comprising 50 and 40 mg/kg body weight
in men and women, respectively. The dynamic turnover of
circulatory Fe of about 30–35 mg/day [2] is associated with
plasma transferrin. Of this, about 80% is in a closed circuitAbbreviations: PHZ, phenylhydrazine; TIBC, total iron binding capacity;
EPO, erythropoietin; TFR, transferrin receptor; DMT1, divalent metal
transporter (nRamp2, DCT1, SCL11a3); NTBI, non-transferrin bound iron;
RE, reticuloendothelial; RBC, red blood cell; Dcytb, duodenal cytochrome b;
KO, selective gene knockout; Hjv, Hemojuvelin; trfhpx/hpx, homozygous
hypotransferrinaemic mouse; hbd, haemoglobin deficite mice; Hfe, haemochro-
matosis type 1 gene; USF, upstream stimulatory factor
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doi:10.1016/j.bbadis.2005.12.007of Fe trafficking from erythrophagocytosis of senescent red
blood cells by macrophages to the bone marrow for
incorporation into new erythrocytes [3]. The remainder
includes non-haem iron-containing enzymes, FeS clusters
and storage forms, ferritin and haemosiderin [4]. Under
normal physiological conditions, the balance of iron
homeostasis is in a dynamic equilibrium between systemic
tissues. Daily absorption of about 1 mg Fe replaces the
limited excretion through normal blood losses, desquamation
of senescent enterocytes, exfoliation of the skin, biliary and
urinary excretion [5]. However, nutritional, physiological,
pathological or mutational aberrations pose challenges to the
body's iron homeostatic mechanisms. These generally
manifest as iron deficiency, overload or maldistribution
disorders. Stimulation of erythropoiesis depends on adequate
plasma iron and iron release from the reticuloendothelial
system (RES). Although the underlying causes of iron
limited anaemia are multifaceted, reduced iron supply and
enhanced activity of haematopoeitic cells are common
prognostic features. The spectrum of these disorders range
from classical nutritional deficiency anaemia to the body's
Fig. 1. Iron absorption regulation. Panel A summarises how hepcidin may act on
the gut to inhibit iron absorption. High levels of hepcidin are associated with low
levels of iron absorption genes, DMT1, Dcytb and ferroportin (hepcidin directly
binds to ferroportin and induces its internalisation and degradation [117]). Panel
B summarises factors that stimulate hepcidin mRNA levels in liver. The size of
the block arrows indicates the relative importance of the effects on iron
absorption. The diagram does not express possible mechanistic interplay (e.g.,
hypothetical involvement of TfR2 as a plasma iron sensor [82]). Different
cytokines have differing (and sometimes controversial) positive and negative
effects on hepcidin levels ([15,32,100,118,119]).
415G.O. Latunde-Dada et al. / Biochimica et Biophysica Acta 1762 (2006) 414–423defence mechanism in the anaemia of chronic disease and a
number of diseases due to mutations of iron transport genes.
2. Regulation of iron absorption
Our understanding of iron absorption regulation has
undergone a revolution in the last 4 years. Over the previous
64 years, since it was proposed that body iron levels were
controlled by regulation of dietary iron absorption [6], progress
in identifying the underlying mechanisms was slow (early work
summarised in [7,8], later work covered by [9,10]). Even the
identification of the haemochromatosis gene (Hfe, [11]),
followed by the principle genes responsible for transporting
non-haem iron (duodenal cytochrome b (Dcytb), divalent metal
transporter 1 (DMT1) for iron uptake into enterocytes,
ferroportin and hephaestin for iron export to plasma, reviewed
in [12]) did not immediately solve the problem. Only the
discovery of the regulatory peptide hepcidin [13–15] produced
the breakthrough and with the discovery that hepcidin
(produced in the liver) directly acts on and regulates the
intestinal iron transporter ferroportin [16] we now have the basis
for a mechanistic understanding of iron absorption regulation
(Fig. 1).
Prior to 2001, extensive work had identified several
physiological factors that regulate iron absorption. The
quantitatively most important, but least studied, is the
developmental regulator, which oversees the close matching
of iron absorption rates to the demands of growth. In mice (and
rats), this means iron absorption reaches a maximal rate at the
time of maximal growth declining by about 4-fold to early
adulthood. One interesting hypothesis about the cause of
haemochromatosis was that normal iron absorption regulation
includes a mechanism to down-regulate iron absorption as an
animal grows to adulthood and that haemochromatosis was
caused by a failure in the inhibitory mechanism [17]. We now
can partly reconcile this down-regulation with the production of
hepcidin which seems to increase during maturation [18].
Another iron absorption regulatory factor is hypoxia [19], a
condition that is also associated with enhanced erythropoiesis.
Several lines of evidence, however, suggest that the increased
iron absorption occurs independently of any erythropoietic
response. These include the time course of the increased iron
absorption, which responds before significant changes in
plasma iron turnover [20], reticulocyte levels [21], or plasma
iron [20,22] although another study has shown a drop in plasma
iron coincident with increased absorption at 8 h of hypoxia [23].
The rise in iron absorption closely parallels the rise in plasma
erythropoietin levels [21]. Further evidence is the finding that
iron absorption can respond to hypoxia even when the bone
marrow is destroyed by radiation [21,24,25] or when erythro-
poietin levels are reduced by partial nephrectomy plus
splenectomy [21,24,25]. Finally, injection of erythropoietin in
normoxic mice to generate a similar erythropoietic response as
seen in hypoxic mice produces little or no increase in iron
absorption [21,25]. The hypoxic response also tends to increase
iron stores [26–28] and plasma iron levels [22,26], and is not
blocked by prior iron loading [23,29], hence is independent ofthe stores regulator. Thus, hypoxia qualifies as an independent
regulator of iron absorption.
Other regulatory factors for iron absorption include preg-
nancy (increased requirements in last trimester [30]), gender
(virgin female rodents have higher iron stores than males [31])
and inflammation. The last of these also seems to involve
hepcidin, which dramatically increases in inflammatory condi-
tions [32] and is a major factor in anaemia of chronic diseases
[33]. However, the majority of investigations of iron absorption
regulation have focussed on the key relationship between iron
supply to the erythron, iron stores and iron absorption. These
are closely integrated as red cell iron is by far the largest iron
compartment in the body, with iron stores being the next largest
in iron replete mammals. Finch [9] enunciated the concept of
‘regulators’ of iron absorption, focussing on the erythroid and
stores regulators. The stores regulator was established from
many studies that show iron absorption changing when iron
stores are altered independently of changes in haemoglobin
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regulator was established from studies showing increased iron
absorption in the absence of anaemia (and therefore no hypoxia)
when erythroid activity was increased, e.g., by erythropoietin
[34]. This occurred even after correction of absorption for
changes in iron stores, and supported many earlier studies in
man and animals (references in [34]) hence an independent
erythroid regulator was hypothesized [9]. Increased erythropoi-
esis is important as the iron overload associated with some
common hereditary anaemias (especially thalassaemias) is a
significant health problem in humans [35] while a derangement
in the stores regulator leading to pathological expansion of iron
stores (even while red cell production and turnover remains
normal) seems to underlie most cases of genetic haemochro-
matosis. Hepcidin seems to provide a final common pathway for
both these regulators being responsive to increased erythropoi-
esis and iron stores [32] and therefore seems to be important in
both these conditions. We still require further data to map all the
known factors that regulate iron absorption to specific genes or
regulatory pathways, however, this will likely be forthcoming in
the near future.
Much of the work described above has been shown to
operate in man as well as rodents, however, work with rodent
models has been essential to the elucidation of iron absorption
regulation [36]. The present review is aimed at describing an
important set of rodent models for the study of iron absorption,
namely those with experimentally or genetically enhanced rates
of erythropoiesis, in particular, we describe in detail phenylhy-
drazine treatment and hypotransferrinaemia, the most exten-
sively studied of these models.
3. Phenylhydrazine-induced haemolytic anaemia
Hereditary or acquired haemolytic anaemia in humans
results from reduced life span or destruction of red blood cells
and a failure of the bone marrow compensatory responses.
Haemolysis of the red blood cells reduces the efficiency of
oxygen delivery which stimulates increased erythropoeisis and
because of the deficit in the Fe supply and haemoglobin levels,
the haemopoietic cells are numerically and morphologically
abnormal. Other features include spherocytosis, polychromasia,
red-cell reticulocytosis, an increase in urinary urobilinogen and
porphyrins [37]. These disorders are associated with ineffective
erythropoiesis and are generally characterized by sustained
enhancement of erythroid activity that promotes increased
gastrointestinal iron absorption and ultimately leads to tissue
iron overload. This model of enhanced erythropoietic activity,
increased iron absorption and tissue iron overload is induced in
experimental animals by the administration of phenylhydrazine
(PHZ). It represents a situation where the triad of haem
catabolism, anabolism and iron absorption is interactive in
balancing systemic iron homeostasis. PHZ induces haemolysis
by a reaction of the oxidized drug with ferrihaemoglobin to
form ferrihaemochrome. This is often accompanied by the
production of reactive oxidants that cause oxidative denatur-
ation of oxyhaemoglobin and generate Heinz bodies [38]. PHZ
also reacts with Hb to cause the dismutation of O2
− and producesH2O2 within the erythrocyte [39]. Alkylation of haem to form
N-phenylhaem and oxidation of Hb affect red cell membrane
integrity resulting in extravascular haemolysis [40]. These
products aggregate as senescent antigen that are recognized by
autologous immunoglobulins [41], thus inducing removal of
cells from the blood by phagocytosis, manifesting a huge
haemochatharsis.
3.1. Haematological indices
Haemolytic anaemia and hyperplastic erythropoiesis induced
by intraperitoneal administration of PHZ is associated with an
initial destruction of about 20% of the circulatory red cell mass
each day. Pronounced anaemia seen 3–5 days after the
administration of PHZ is characterized by decreased haemato-
crit, Hb, red cell count and mean corpuscular volume [42,43].
As erythropoietin (EPO) production is increased [44,45],
erythroid marrow expands, and both blood flow and erythroid
progenitor cells iron uptake is increased [45]. Proliferation of
the erythroid marrow results in increased reticulocytes in
circulation. Moreover, PHZ anaemia is associated with
hyperferraemia, increased total iron binding capacity (TIBC)
and a 3- to 4-fold increase in iron turnover [46,47]. Increased
haemopoietic iron demands create an imbalance between
marrow iron needs and supply resulting in elevated RBC
protoporphyrin [48,49]. Iron loss is extremely low in PHZ-
treated animals [50], therefore increased absorption, erythrocyte
catabolism and reticuloendothelial circulation result in in-
creased serum iron. Erythrophagocytosis of haemolysed
erythrocytes contributes to elevated serum iron and this iron
is more readily available for haemopoietic stem cells for Hb
production than that derived from iron stores [9,48]. While
transferrin receptor (TFR1) in the bone marrow, blood and
spleen of rats increased about 4-fold [51], serum diferric
transferrin was significantly reduced [52] in PHZ-treated rats.
The initial decrease in diferric transferrin preceded a decrease in
hepcidin expression (discussed later) and was thereafter
elevated on days 6 and 7 of PHZ treatment [52].
3.2. Splenic and hepatic iron metabolism in PHZ-treated
animals
Extramedullary haemopoiesis and increased erythrophago-
cytosis are features exhibited in the spleen during acute
haemolysis induced by PHZ. In consequence, morphological
changes include splenomegaly and congestion of haemosiderin
deposits [46]. Catabolism of haemolysed red blood cells is
associated with increased expression and activity of haem
oxygenase 1 [53] suggesting increased capacity for degradation
of Hb products in the spleen. Splenic iron level was therefore
increased in rats after PHZ treatment [54]. DMT1 and TFR1
mRNA expressions were increased in the spleen of PHZ-treated
mice [45,55]. Increased splenic erythrophagocytosis results in a
net flux of iron into the circulation from haemolysed red blood
cells. While the mechanism of iron exchange between
macrophages and transferrin is still undefined, ferroportin
mRNA increased in the spleen of PHZ-treated mice [45],
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Hepatic non-haem iron levels increased significantly after PHZ
treatment and this was sustained 7 days after haemolysis [52].
Liver iron accumulates due to increased absorption driven by
haematopoeitic activity in PHZ-treated animals. Liver iron
accumulates initially due to haemolysis, although later on,
absorbed iron may also be diverted to the liver. Saturation of
serum transferrin has been shown to preferentially divert
absorbed iron to the hepatocyte [56,57]. Iron deposition in the
liver could in addition to the TFR/DMT1 routes, be due to
influx of non-transferrin bound iron (NTBI). Furthermore, as
PHZ-induced haemolysis is stressful and produces haem-
derived toxic reactants, the expressions of acute phase proteins
hemopexin, haptoglobulin and CD163 in the hepatocytes
[58,59] and the kidneys [60,61] are increased. These organs
mop up the haem-derived products from circulation. The
sequestration of Hb iron in the liver of the transferrin-saturated
animal is analogous to patients manifesting ineffective
erythropoiesis and hepatocyte iron overload [61]. Anaemias,
such as thalassaemia, sideroblastic and some dyserythropoietic
anaemias, are characterized by high intestinal iron absorption
most probably due to enhanced erythropoiesis. However,
efficient iron recycling typifies hereditary spherocytosis with
comparable iron turnover as the conditions above [44] to
maintain a form of compensated haematological indices.
Compensation and normality also ensue during chronic
hereditary or drug-induced haemolytic anaemia (Table 1) [62].
3.3. Iron absorption and regulation during PHZ-induced
haemolytic anaemia
Increased gastrointestinal absorption of iron is well docu-
mented during haemolysis in experimental animals [64,65] and
humans [61]. Enhanced absorption of iron is associated with
acute enlargement of the reticulocyte pool due to stimulated
erythropoiesis [22], which ultimately leads to tissue iron
overload [47,54]. Increased iron absorption in the presence of
elevated hepatic stores defines the importance of the erythroid
drive overriding iron storage in the regulation of iron absorption
[9]. Iron absorption in PHZ-treated animals increased about 2-
fold 3–5 days after treatment and thereafter declined to the
control level by the 7th day [52]. Both uptake and transfer
processes were enhanced during this adaptation [45]. An earlier
study had demonstrated both morphological and physiological
adaptation of the brush border of the duodenum of PHZ-treatedTable 1
Quantitative representation of Fe metabolism during chronic haemolytic
condition in man (mg, adapted from [63])
Normal Haemolytic anaemia
Iron absorption 1 2
Erythrocyte 2500 1500
Plasma iron 4 5
Fe loss 1 1.5
Body stores 1000 2000
RE, RBC destruction 20 150
Bone marrow, RBC production 20 150animals that favoured increased iron absorption [64]. This was
the development of an expanded absorptive surface area
coupled with an enhanced electrical driving force in the
epithelia of the enterocytes. Recent studies [45,52] have further
shown that iron transport genes were up-regulated when mice
and rats were treated with PHZ. Moreover, immunohistochem-
ical staining in these mice revealed no morphological changes
in the duodenum but an enhanced expression of the proteins
involved in iron absorption [45,52].
The time-course of iron absorption due to stimulated
erythropoiesis induced by PHZ correlated significantly with
the expression of Dcytb, DMT1 and ferroportin. Consequently,
the signal effecting increased iron absorption in this model
enhanced the expression and activities of these proteins.
Moreover, the time lag before the increase in iron absorption
that was apparent after the administration of PHZ was the time
required for the body to detect the need for more iron rather than
that due to maturation, migration and modulation of iron
transport genes [54]. Hepcidin, a liver synthesized antimicrobial
peptide discussed above as a negative regulator of iron
absorption, was actually down-regulated during haemolysis
induced by PHZ [32,44,54]. The attenuation of hepcidin
production when erythropoiesis is iron restricted is also evident
in Trfhpx/hpx mice [33], hypoxia [66,67] and in pregnant rats
[68]. It was not surprising that an earlier notion of a hormonal
factor produced no effect in recipient mice that received serum
from Trfhpx/hpx mice [69] and the effect seen when recipient
animals received blood from PHZ-treated animal [9,65] was
attributed to blood cells rather than the plasma. This was
perhaps due to increased iron requirements of the enlarged
reticulocyte compartment in the animals. It was actually
speculated then that the absence in the plasma of an erythroid
regulator was due to inactivation [69], however, the alternative
hypothesis of an inhibitory humoural factor [29,70] has turned
out to be the explanation. Although inverse correlative
expressions of hepcidin and iron absorption are consistent in
the different models, the magnitude of hepcidin expression is
quite variable (Fig. 3). This might be correlated to the rate and
level of hepcidin interaction with ferroportin in macrophages
and enterocytes. Other compounding variables include varying
iron concentrations of commercial laboratory chow and strain
differences in liver iron levels, which might both be significant
in the basal level of hepcidin expression (Fig. 3).
The hepatocyte is now recognized as the central control co-
ordinator of the body's iron homeostasis [71,72]. Rat liver
transplantation studies pointed to this function [73] but the
determining factor was elusive at the time. Unlike the other
forms of iron overload disorders, Trfhpx/hpx and PHZ-treated
models typify situations where the different anatomical sites of
iron utilization (bone marrow), storage (liver) and absorption
(intestine) interact, communicate and are co-ordinated. The
interconnecting linkage molecule, the sensor, hypothesized as
diferric transferrin conveys the bone marrow activity to hepatic
macrophages or parenchymal cells to modulate hepcidin
expression [74]. The interplay of Hfe, TFR1, TFR2 and diferric
transferrin in a signaling cascade regulating hepcidin expression
has been discussed extensively by Frazer et al. [71]. The
Fig. 2. Relative total body iron increase in mice with iron metabolism gene
mutations. Total body iron in mice was estimated by assuming liver iron stores
(measured by liver non-haem iron measurements) are one third of total body iron
stores [120], the rest being in bone marrow plus spleen and in muscle [121].
Haem iron was estimated from haemoglobin, blood volume, (estimated from
data in [122] and age variations estimated from rat data [123,124]), muscle mass
(taken as 0.43 times body weight, [120,125]) and data for muscle myoglobin in
[126,127]. Additional (non-variant) tissue haem and non-haem iron pools were
included in the calculation. These were estimated from the body weight and data
in refs. [120,121,125,128], however, they contribute little to the relative increase
in total body iron in iron overload. Each model total body iron is expressed
relative to its own age, gender and strain-matched controls. Mouse strains vary
in total body iron as shown by data in [129] and the present calculation shows
SWR mice have 18% higher total body iron than, e.g., C57BL/6J. Source of
tissue iron data: erythropoietin deficient (Epo def) [104], Beta thalassaemic (beta
thal) [99]; Hfe knockout (HfeKO) [130], Schumann, K., Srai, S.K. and Simpson,
R.J. unpublished observation; Hfe C282Y mutated (Hfe-C282Y) [131,132]; Hfe
KO on AKR background [133], haemoglobin and body weights estimated;
Trfhpx/hpx [94,99,105]; Haemojuvelin knockout (Hjv KO) [100], haemoglobin
and body weight estimated from [132] data; upstream stimulatory factor
knockout (hepcidin knockout) (USF KO) [14], body weight estimated; Liver
volumes were estimated from data in [134–139].
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be inactivated along with hepcidin expression [75,76] in
juvenile haemochromatosis. Interestingly, the interaction of
ferroportin and these molecules, before the discovery of
hepcidin, was hypothesized as being in the macrophages and
the duodenum [77]. Ferroportin (now known as the target
protein of hepcidin action) and basolateral efflux of iron have
indeed been speculated as rate limiting in the regulation of
intestinal absorption of iron [78–80] however this only seems to
be the case in certain physiological states [81]. A decrease in
diferric transferrin preceded the decrease in hepatic hepcidin
level when erythropoietic demands were enhanced by PHZ-
induced haemolysis [52]. Thus iron deficiency was sensed in
the absence of diferric transferrin, Hfe is proposed to bind to
TFR1, and its signal to induce hepatic hepcidin expression thus
abrogated [82].
The roles of serum transferrin and transferrin saturation in
the regulation of iron absorption have earlier been investigated
[83–85] even though all attention, again, was focused on the
gastrointestinal tract. This is particularly relevant to Trfhpx/hpx
mice model and it is discussed further in the second part of this
review. Stimulated haemopoietic activity is enhanced in PHZ-
treated animals by increased EPO production [44] and EPO
injection has been shown to correlate indirectly with decreased
hepatic hepcidin expression [86]. It is known that EPO does not
exert a direct effect on the intestine [25] and its effect on
hepcidin expression in the hepatocyte is also not known [87].
EPO is however a potent component of the erythropoietic
regulator of intestinal absorption of iron which represses hepatic
hepcidin expression to cause enhanced iron absorption in the
gut. The independence of this regulator from iron stores was
also confirmed in PHZ-treated mice, as the inhibitory effect of
PHZ on hepatic hepcidin expression was not obliterated when
these mice were loaded with iron dextran [32]. The complexities
and the detailed molecular regulation of hepcidin expression in
drug-induced haemolytic anaemia and other models of iron
absorption await elucidation.
4. Hypotransferrinaemic mice—the mouse model with
highest sustained iron absorption and highest recorded
spontaneous tissue iron loading
The hypotransferrinaemic mouse (trfhpx/hpx), originally
characterized by Bernstein [88], has been a very useful animal
model for the study of iron metabolism. The mice have a point
mutation in a transferrin mRNA splice donor site [89] that leads
to incorrect splicing [90] with almost complete loss of
transferrin synthesis [89].
Homozygotes have less than 2% of normal transferrin levels
[88] with a resultant severe hypochromic anaemia and
concomitant parenchymal iron overload with contrasting low
iron levels in spleen and bone marrow [88,91,92]. The pattern of
tissue iron overload resembles the haemochromatosis pheno-
type but the latter does not have concomitant anaemia [88,92].
In mice, the homozygous hypotransferrinaemic phenotype has
much higher levels of tissue and body iron loading than is seen
with homozygous Hfe knockout (KO) or the C282Y mutation(Fig. 2). On the other hand, heterozygous trfhpx/hpx mice are
effectively normal. Part of the explanation for the mildness of
the trfhpx/+ phenotype is a partial compensation of transferrin
turnover such that the steady state level of transferrin in the
heterozygote is 75% of normal [26,93].
Trfhpx/hpx mice die within 2 weeks of birth unless life-sparing
injections of transferrin (or plasma, or serum) are given [88].
The mice can live for near normal life spans if given approx. 1
mg of transferrin per week [88,94]. This is sufficient to maintain
transferrin levels at b2% of normal for most of their life, yet
they live with a reduced body size, cardiomegaly, splenomeg-
aly, increased iron stores and a chronic anaemia [88,94]. If
transferrin injections are stopped, the mice die with massive iron
overload after a few months [89].
The phenotype of the mice illustrates several features of iron
metabolism. The almost complete absence of transferrin results
in drastically reduced incorporation of iron into red cells,
demonstrating the high level of dependence of these cells on the
transferrin-TFR1-DMT1 iron uptake system. In contrast, some
other tissues have near normal iron levels (e.g., brain, [95]),
while a select group of cells are massively iron overloaded,
Fig. 4. Duodenal Expression of Dcytb, DMT1-IRE and Ferroportin in Hpx mice.
Real-time PCR analysis of duodenal Dcytb, DMT1-IRE (Pb0.001) and
ferroportin mRNA expression in Hpx mice. Quantitative measurement of each
gene was derived from a standard curve constructed from known amounts of
PCR product. Data are normalized to the expression of the house-keeping 18S
gene and are expressed as means±S.E.M.
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extent, muscle cells [94]. This latter finding suggests that many
tissues, especially those that develop iron overload [96–98] can
take up iron via NTBI pathways.
Trfhpx/hpx mice have the highest reported level of iron
absorption of the hereditary mouse models, presumably due to
the complete absence of hepcidin expression ([33,99], Fig. 3).
Even hepcidin knock-out mice do not seem to reach the levels of
tissue iron seen in trfhpx/hpx mice ([14,94], Fig. 2), although no
direct, background strain and diet-matched comparison has
been made. A recent report of Hemojuvelin KO mice (Hjv−/−,
[100]) suggests they match the trfhpx/hpx mouse in iron loading,
although little data were reported on body weights and
haemoglobin levels in these mice except that they appeared
normal.
This extremely high level of absorption in trfhpx/hpx mice was
used by McKie et al. to identify several genes implicated in iron
absorption including Dcytb [101], Ireg1 (ferroportin, [102]) and
HCP1 [103].
Fig. 3 shows the dramatic decrease in liver hepcidin mRNA
and Fig. 4 the increase in iron absorption genes in trfhpx/hpx
mice. Comparison of trfhpx/hpx mice with thalassaemic mice and
erythropoietin (EPO) deficient mice illustrates the complexity
of iron absorption regulation. EPO deficient mice have similar
haemoglobin levels (without the enhanced erythropoiesis) to the
trfhpx/hpx mouse [104], yet iron absorption is increased many
times more in the trfhpx/hpx mouse. Clearly, factors other than
anaemia are important. The thalassaemic mice additionally have
increased plasma iron turnover, considered a stimulant for iron
absorption, while EPO-deficient mice do not. Thalassaemic
mice, however, still have far lower iron absorption rates than
those seen in trfhpx/hpx mice [99,105]. The anaemia in beta
thalassaemic mice is less severe than trfhpx/hpx mice, however,
anaemia alone in mice does not increase iron absorption greatly.
Hepcidin levels are decreased in beta thalassaemic mice [106].
Hepcidin levels have not yet been studied in EPO-deficient
mice but a similar inherited mild anaemia in mice withoutFig. 3. Hepatic hepcidin mRNA levels in PHZ-treated and Hpx mice. Real-time
PCR analysis of liver hepcidin mRNA expression in PHZ-treated and Hpx mice.
Hepcidin mRNA expression was significantly reduced (Pb0.05) in PHZ-treated
and Hpx mice. Quantitative measurement of hepcidin was derived from a
standard curve constructed from known amounts of PCR product. Data are
normalized to the expression of the house-keeping 18S gene and are expressed
as means±S.E.M.enhancement of erythroid iron uptake has been studied recently
(haemoglobin deficit mice, hbd [107]). Like EPO-deficient
mice, hbd mice have raised plasma iron but no increase in net
absorption of iron. Hbd mice had a small increase in hepcidin
levels, in line with the increased plasma iron [107] and
relatively unchanged iron absorption.
As discussed above iron absorption is regulated by iron
stores, erythroid demand and hypoxia. The latter two alone
seem to be unable to enhance iron absorption to the levels seen
in trfhpx/hpx mice where iron stores are increased (thus tending to
decrease iron absorption) [105], thus it seems another factor is
important in trfhpx/hpx mice.
Perhaps, the iron deficiency in the bone marrow of trfhpx/hpx
mice is important. This raises the question of how this is
communicated from bone marrow to the liver, where hepcidin
levels are so low, despite the high iron stores there. Another
obvious factor is the absence of circulating diferric transferrin.
This has been suggested to be a factor that regulates hepcidin
synthesis, possible acting partially via TFR2, absence of which
seems to lead to iron overload [71,108,109].
In 1999, we investigated the role of transferrin in regulating
iron absorption in trfhpx/hpx mice by correcting the chronic
anaemia with daily transferrin injections for three weeks from
weaning [85]. This was an attempt to ‘normalise’ the trfhpx/hpx
mice as much as possible. The transferrin injections were then
stopped allowing transferrin to disappear from the circulation
(the half life of transferrin in mice is only about 1 day). Iron
absorption was measured before and 7 days after cessation of
the injections. It was found that haemoglobin levels had not
changed as the half life of red cells in mice is 10 days or more
[110]. Iron stores were also unchanged, yet iron absorption was
significantly increased by the reduced levels of transferrin. This
study preceded the discovery of hepcidin hence no measure-
ments of that were made but presumably levels of this key
regulator had fallen as transferrin levels fell.
420 G.O. Latunde-Dada et al. / Biochimica et Biophysica Acta 1762 (2006) 414–423Can we reproduce the enhanced iron absorption seen in
trfhpx/hpx mice with experimental treatments of genetically
normal mice? Experimentally enhanced erythropoiesis by
chemical haemolysis, as described in detail above, produces
only mild increases in iron absorption. Hypoxia can, in some
mouse strains, produce a large response [21], however
hypotransferrinaemia has a greater effect than hypoxia when
compared in the same mouse strain [26,99,105]. Iron defi-
ciency in mice usually involves dietary iron restriction, whereas
trfhpx/hpx mice have high iron absorption rates when fed diets
with normal iron levels. Alteration in dietary iron level can, by
itself, alter iron absorption by a local mechanism at the level of
the gut [78].
All this is tantalizing evidence that hepcidin may not quite
provide the complete story of systemic iron absorption
regulation. Clearly, hepcidin is of major importance, as shown
by comparison of HjvKO, hepcidinKO and trfhpx/hpx mice. Until
further work on iron absorption in hepcidinKO mice, or a
careful comparison of trfhpx/hpx and hepcidinKO or HjvKOmice
is performed on the same genetic background and diets, it
remains possible that iron absorption is not maximally enhanced
simply by loss of hepcidin. Perhaps, the absence of diferric
transferrin in the plasma can also directly affect the gut. Many
studies failed to provide evidence for such an effect [84],
although these were all acute studies. Perhaps, there is an
additional signal from the bone marrow to the gut such as
amino-laevulinic acid [67,111]. Perhaps, intestinal epithelial
cells can respond directly to hypoxia as well as via hepcidin.
Most cells seem able to respond to hypoxia [112] and cultured
epithelial cells also have a hypoxic response [113] and can
regulate iron transport in response to cytokines [114,115] which
are altered in hypoxia. We have also found indirect evidence for
a local responsiveness to IL-6 in the duodenum of mice [116].
Finally, local responsiveness of the gut to ingested iron is also
important [78] and implies a degree of local regulation of iron
absorption by the gut in response to enterocyte iron levels.
In conclusion, the discovery of hepcidin and its mechanism
of action has provided a potential answer to the mystery of iron
absorption regulation, especially in well-studied models like
Trfhpx/hpx mice and PH2-treated animals where the liver has
moved to centre stage. Further careful studies can deliver a
complete description of the regulatory mechanism(s).
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